Clinical Trial

Brimonidine Eye Drops in the Prevention of Myopia Progression

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated May 30, 2025 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.
Summary
Study to determine the efficacy of alpha-2 adrenergic drugs (brimonidine) in the prevention of myopia progression. Given that the drugs used so far have limited efficacy and side effects (loss of near vision, photophobia), it may be an interesting contribution to such treatment at low cost, and to avoid the expense of managing the complications of myopia that develop throughout life.
Trial Details
NCT Number NCT06996236
Lead Sponsor Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Conditions Myopia
Enrollment 40 participants
Start Date 2025-07
Primary Completion 2026-07 (estimated)
Study Completion 2027-07 (estimated)
Updated on ClinicalTrials.gov 2025-05-30